Altering protein turnover in tumor cells: New opportunities for anti-cancer therapies

被引：38
|
作者：
Demarchi, F
Brancolini, C
机构：
[1] Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, I-33100 Udine, Italy
[2] Lab Nazl Consorzio Interuniv Biotecnol, I-34100 Trieste, Italy
来源：
DRUG RESISTANCE UPDATES | 2005年 / 8卷 / 06期
关键词：
apoptosis; caspases; IAP; IBM; bortezomib; bcl-2; mitochondria; death receptors; apoptosome; hsp; p53; NF-kappa B; noxa; Mcl-1; ubiquitin; proteasome;
D O I：
10.1016/j.drup.2005.12.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The promising effects of the proteasome inhibitor bortezomib (Veleade, PS-341) in the treatment of certain types of cancer have fired up the interest on this multicatalytic proteolytic machinery. A number of recent reviews thoroughly describe various aspects of the ubiquitin-proteasome system and its importance in the control of cell growth and tumorigenesis. Here, we will focus on recent data unveiling a link between the proteasome and some elements of the apoptotic machinery including Bcl-2 members, caspases, IAPs and IAP antagonists. Perturbing their turnover significantly contributes to the apoptotic response and the anti-neoplastic activity of proteasome inhibitors. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码：359 / 368
页数：10
相关论文
共 50 条
  • [1] New anti-cancer therapies, new opportunities for infection
    Potter, M
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 1999, 12 (04) : 359 - 363
  • [2] Anti-cancer therapies targeting the tumor stroma
    Valeska Hofmeister
    David Schrama
    Jürgen C. Becker
    [J]. Cancer Immunology, Immunotherapy, 2008, 57 : 1 - 17
  • [3] Anti-cancer therapies targeting the tumor stroma
    Hofmeister, Valeska
    Schrama, David
    Becker, Juergen C.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (01) : 1 - 17
  • [4] Translating Tumor Metabolism into New Diagnostics and Novel Anti-Cancer Therapies
    Lisanti, M. P.
    Sotgia, F.
    [J]. ACTA PHYSIOLOGICA, 2014, 210 : 16 - 16
  • [5] Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia:: Implications for anti-cancer therapies
    Martinive, Philippe
    Defresne, Florence
    Bouzin, Caroline
    Saliez, Julie
    Lair, Florence
    Gregoire, Vincent
    Michiels, Carine
    Dessy, Chantal
    Feron, Olivier
    [J]. ACTA CLINICA BELGICA, 2008, 63 (01): : 55 - 55
  • [6] Cancer stem cells: Toward novel anti-cancer therapies?
    Blomme, Eric A. G.
    [J]. VETERINARY JOURNAL, 2008, 177 (03): : 303 - 304
  • [7] Potential of Mesenchymal Stem Cells in Anti-Cancer Therapies
    Kostadinova, Milena
    Mourdjeva, Milena
    [J]. CURRENT STEM CELL RESEARCH & THERAPY, 2020, 15 (06) : 482 - 491
  • [8] New anti-cancer strategies: Epigenetic therapies and biomarkers
    Balch, C
    Montgomery, JS
    Paik, HI
    Kim, S
    Huang, THM
    Nephew, KP
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 : 1897 - 1931
  • [9] Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies
    Thakur, Chitra
    Qiu, Yiran
    Fu, Yao
    Bi, Zhuoyue
    Zhang, Wenxuan
    Ji, Haoyan
    Chen, Fei
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Macrophage responses to hypoxia - Implications for tumor progression and anti-cancer therapies
    Lewis, C
    Murdoch, C
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2005, 167 (03): : 627 - 635
12345